23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › KYMERA THERAPEUTICS INC. › 2023-2024

KYMERA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 182Asset managers, any item
  • 1,552Fund votes
  • June 18, 2024Meeting date

Results at a glance

Meeting of June 18, 2024: 6 items on KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024: 3 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (12.2%, 11.8% against); 1 other board item (45.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KYMERA THERAPEUTICS INC.

These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KYMERA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 18, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Pamela Esposito, Ph.D. 49,219,482---- 6,587,8191,855,694 88%Passed (calculated)—
Elect Director: Gorjan Hrustanovic, Ph.D. 48,998,105---- 6,809,1961,855,694 88%Passed (calculated)—
Elect Director: Victor Sandor, M.D.C.M. 51,424,753---- 4,382,5481,855,694 92%Passed (calculated)—
2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers 54,201,7341,599,5116,056 --1,855,694 97%Approved—
3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm 57,657,1244,2711,600 ---- 99.9%Approved—
4. Approval of Amendment No 30,565,16525,232,9349,202 --1,855,694 54.8%Approved—

Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.

How asset managers voted at the KYMERA THERAPEUTICS INC. 2023-2024 meeting

182 asset managers disclosed a vote on at least one KYMERA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Gorjan Hrustanovic, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 48,998,105WITHHELD: 6,809,196
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 48,998,105 for, 6,809,196 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 16,166,074 for, 3,303,243 withheld, 29,852 abstained.

FORWITHHOLD
FOR: 16,166,074ABSTAIN: 29,852WITHHOLD: 3,303,243
Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,141,7630 00For
T. Rowe Price4,948,3440 00For
Fidelity541,9230 02,223,395Mixed
State Street1,200,0300 01,705For
BlackRock729,3340 00For
Charles Schwab356,1190 00For
MFS00 0346,166Withhold
Hartford208,4950 00For
JPMorgan165,8570 00For
Direxion Shares ETF Trust00 0153,457Withhold
First Trust00 0135,718Withhold
Equitable76,3560 040,750Mixed
John Hancock93,2340 14,7300Mixed
TIAA95,1620 00For
Dimensional00 090,702Withhold
AIG/SunAmerica00 068,534Withhold
Northwestern Mutual63,5330 00For
Neuberger Berman62,5430 00For
Lincoln Financial31,9000 022,632Mixed
QUANTITATIVE MASTER SERIES LLC52,7030 00For
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse39,3900 011,855Mixed
American Century00 048,165Withhold
Transamerica47,1210 00For
ProShares00 041,033Withhold

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Elect Director: Pamela Esposito, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 49,219,482WITHHELD: 6,587,819
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Pamela Esposito, Ph.D.”): 49,219,482 for, 6,587,819 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 16,167,644 for, 3,301,673 withheld, 29,852 abstained.

FORWITHHOLD
FOR: 16,167,644ABSTAIN: 29,852WITHHOLD: 3,301,673
Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,141,7630 00For
T. Rowe Price4,948,3440 00For
Fidelity541,9230 02,223,395Mixed
State Street1,200,0300 01,705For
BlackRock729,3340 00For
Charles Schwab356,1190 00For
MFS00 0346,166Withhold
Hartford208,4950 00For
JPMorgan165,8570 00For
Direxion Shares ETF Trust00 0153,457Withhold
First Trust00 0135,718Withhold
Equitable76,3560 040,750Mixed
John Hancock93,2340 14,7300Mixed
TIAA95,1620 00For
Dimensional00 090,702Withhold
AIG/SunAmerica00 068,534Withhold
Northwestern Mutual63,5330 00For
Neuberger Berman62,5430 00For
Lincoln Financial31,9000 022,632Mixed
QUANTITATIVE MASTER SERIES LLC52,7030 00For
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse39,3900 011,855Mixed
American Century00 048,165Withhold
Transamerica47,1210 00For
ProShares00 041,033Withhold

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Elect Director: Victor Sandor, M.D.C.M.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 51,424,753WITHHELD: 4,382,548
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Victor Sandor, M.D.C.M.”): 51,424,753 for, 4,382,548 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 17,123,050 for, 2,367,250 withheld, 8,869 abstained.

FOR
FOR: 17,123,050ABSTAIN: 8,869WITHHOLD: 2,367,250
Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,141,7630 00For
T. Rowe Price4,948,3440 00For
Fidelity541,9230 02,223,395Mixed
State Street1,201,6050 0130For
BlackRock729,3340 00For
Charles Schwab356,1190 00For
MFS346,1660 00For
Hartford208,4950 00For
JPMorgan165,8570 00For
Direxion Shares ETF Trust153,4570 00For
First Trust135,7180 00For
Equitable76,3560 040,750Mixed
John Hancock107,9640 00For
TIAA95,1620 00For
Dimensional00 090,702Withhold
AIG/SunAmerica68,5340 00For
Northwestern Mutual63,5330 00For
Neuberger Berman62,5430 00For
Lincoln Financial50,6420 03,890Mixed
QUANTITATIVE MASTER SERIES LLC52,7030 00For
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse51,2450 00For
American Century48,1650 00For
Transamerica47,1210 00For
ProShares41,0330 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Approval of Amendment No

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

54.8% Approved · of votes cast

FOR 54.8%AGAINST
FOR: 30,565,165AGAINST: 25,232,934
Details: description as filed, official tally, votes by 70 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.

KYMERA THERAPEUTICS INC.’s own tally for this item (“4. Approval of Amendment No”): 30,565,165 for, 25,232,934 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Approval of Amendment No. 1 to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan The shareholders of the Company approved the amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan to amend the evergreen provision to provide that any of the Com…”
Support: 54.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 2,919,019 for, 16,575,774 against, 4,376 abstained.

FORAGAINST
FOR: 2,919,019AGAINST: 16,575,774ABSTAIN: 4,376
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,433,3904,708,373 00Mixed
T. Rowe Price04,948,344 00Against
Fidelity02,765,318 00Against
State Street1,2551,200,480 00Against
BlackRock0729,334 00Against
Charles Schwab0356,119 00Against
MFS0346,166 00Against
Hartford208,4950 00For
JPMorgan0165,857 00Against
Direxion Shares ETF Trust0153,457 00Against
First Trust0135,718 00Against
Equitable0117,106 00Against
John Hancock45,33262,632 00Mixed
TIAA095,162 00Against
Dimensional090,702 00Against
AIG/SunAmerica068,534 00Against
Northwestern Mutual63,5330 00For
Neuberger Berman062,543 00Against
Lincoln Financial054,532 00Against
QUANTITATIVE MASTER SERIES LLC052,703 00Against
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse051,245 00Against
American Century048,165 00Against
Transamerica047,121 00Against
ProShares041,033 00Against

Showing the 25 largest of 70 asset managers. All 70 are in the interactive database (link above).

Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 54,201,734AGAINST: 1,599,511

Prior year: 96.6% for (June 15, 2023 meeting) ▲ 0.6 pts

Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers;

KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,201,734 for, 1,599,511 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 70 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers;” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,141,7630 00For
T. Rowe Price4,948,3440 00For
Fidelity2,765,3180 00For
State Street1,201,249486 00For
BlackRock729,3340 00For
Charles Schwab356,1190 00For
MFS0346,166 00Against
Hartford208,4950 00For
JPMorgan165,8570 00For
Direxion Shares ETF Trust153,4570 00For
First Trust135,7180 00For
Equitable117,1060 00For
John Hancock107,9640 00For
TIAA95,1620 00For
Dimensional90,7020 00For
AIG/SunAmerica68,5340 00For
Northwestern Mutual63,5330 00For
Neuberger Berman62,5430 00For
Lincoln Financial54,5320 00For
QUANTITATIVE MASTER SERIES LLC52,7030 00For
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse51,2450 00For
American Century048,165 00Against
Transamerica47,1210 00For
ProShares41,0330 00For

Fund voting reports, all 70 managers: 19,071,765 for, 456,735 against, 1,184 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 135 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers;” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
New York Life11,000,0000 00For
T. Rowe Price6,124,1850 00For
BAKER BROS. ADVISORS LP5,995,9280 00For
Atlas Venture Life Science Advisors, LLC5,377,3620 00For
BVF INC/IL5,161,8010 00For
Fidelity3,960,9530 00For
Wellington3,744,5010 00For
Avoro Capital Advisors LLC1,891,2430 00For
State Street1,707,81213,071 00For
Redmile Group, LLC1,663,2670 00For
Rock Springs Capital Management LP1,505,7500 00For
BlackRock1,302,2207,803 00For
GEODE CAPITAL MANAGEMENT, LLC579,9790 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/0374,730 00Against
Charles Schwab356,1190 00For
Candriam S.C.A.0328,291 00Against
UBS0291,195 00Against
JPMorgan277,8470 00For
Aquilo Capital Management, LLC253,4280 00For
Northern Trust197,79325 00For
Deep Track Capital, LP189,8100 00For
DE Shaw166,5460 00For
Rafferty Asset Management, LLC153,4570 00For
JENNISON ASSOCIATES LLC148,1630 00For
GREAT LAKES ADVISORS, LLC130,7520 00For

Institutional-manager reports, all 135 managers: 52,922,639 for, 1,346,566 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 57,657,124AGAINST: 4,271

Prior year: 100.0% for (June 15, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 70 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and

KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 57,657,124 for, 4,271 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 19,528,500 for, 1,184 abstained.

FOR
FOR: 19,528,500ABSTAIN: 1,184
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at KYMERA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,141,7630 00For
T. Rowe Price4,948,3440 00For
Fidelity2,765,3180 00For
State Street1,201,7350 00For
BlackRock729,3340 00For
Charles Schwab356,1190 00For
MFS346,1660 00For
Hartford208,4950 00For
JPMorgan165,8570 00For
Direxion Shares ETF Trust153,4570 00For
First Trust135,7180 00For
Equitable117,1060 00For
John Hancock107,9640 00For
TIAA95,1620 00For
Dimensional90,7020 00For
AIG/SunAmerica68,5340 00For
Northwestern Mutual63,5330 00For
Neuberger Berman62,5430 00For
Lincoln Financial54,5320 00For
QUANTITATIVE MASTER SERIES LLC52,7030 00For
MML SERIES INVESTMENT FUND52,0810 00For
Brighthouse51,2450 00For
American Century48,1650 00For
Transamerica47,1210 00For
ProShares41,0330 00For

Showing the 25 largest of 70 asset managers. All 70 are in the interactive database (link above).

Largest KYMERA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,353,146 shares outstanding at the time of that meeting.

Fund voting reports: top KYMERA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 11.64%
2T. Rowe Price 8.07%
3Fidelity 4.51%
4State Street 1.96%
5BlackRock 1.19%
6Charles Schwab 0.58%
7MFS 0.56%
8Hartford 0.34%
9JPMorgan 0.27%
10Direxion Shares ETF Trust 0.25%
Institutional-manager reports: top KYMERA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1New York Life 17.93%
2T. Rowe Price 9.98%
3BAKER BROS. ADVISORS LP 9.77%
4Atlas Venture Life Science Advisors, LLC 8.76%
5BVF INC/IL 8.41%
6Fidelity 6.46%
7Wellington 6.10%
8Avoro Capital Advisors LLC 3.08%
9State Street 2.80%
10Redmile Group, LLC 2.71%

Reported KYMERA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KYMERA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
T. Rowe Price6,332,012 10.32%Form 13F, quarter ended March 31, 2024
Entities affiliated with BVF Partners L.P.6,151,900 10.03%Proxy statement (DEF 14A), proxy filed April 24, 2024
Baker Bros. Advisors LP6,001,262 9.78%Schedule 13D, filed August 22, 2024
Entities affiliated with Baker Bros. Advisors LP5,997,706 9.78%Proxy statement (DEF 14A), proxy filed April 24, 2024
Felix Baker, Ph.D.5,997,706 9.78%Proxy statement (DEF 14A), proxy filed April 24, 2024
FMR (Fidelity)5,879,611 9.58%Form 13F, quarter ended March 31, 2024
Vanguard Group5,421,722 8.84%Form 13F, quarter ended March 31, 2024
Entities affiliated with Atlas Venture Partners5,377,362 8.76%Proxy statement (DEF 14A), proxy filed April 24, 2024
BlackRock4,365,448 7.12%Form 13F, quarter ended March 31, 2024
Wellington Management4,293,697 7.00%Form 13F, quarter ended March 31, 2024

Percentages above are of 61,353,146 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KYMERA THERAPEUTICS INC.'s shareholder meeting held June 18, 2024, in the 2023-2024 proxy season, 182 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,552 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers; — KYMERA THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “KYMERA THERAPEUTICS (KYMR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/kymera-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.